ATLASATLAS fair value
ATLAS has no fair value for this stock today.
GRI Bio (GRI)
GRI Bio stock price today, ATLAS forecast and fair value
Healthcare · Biotechnology · NASDAQ
$1.50▲ +3.45%
Prices as of Oct 26, 2026 · USD
Chance of rising in 1 month
44%
that it ends higher than today in 21 sessions
0%coin flip 50%100%
This is just the summary. See everything on GRI Bio in ATLAS
ATLAS's own quantitative analysis, all in one place.
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
See everything included
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
On GRI Bio
- Simulation and expected rangeThousands of simulated scenarios: how far the price could rise or fall.
- Officers and shareholdersWho runs the company and which funds hold its shares.
- Customer and supplier mapWho it does business with, from its own filings.
- Valuation and financialsFair value step by step, quarterly accounts and upcoming events.
- NewsThe latest on the company, in one place.
And for you
- ATLAS builds your portfolioAnswer a short test and get portfolios that fit you.
- AlertsWe let you know when something changes in your stocks.
- Crisis simulatorHow your portfolio would do in a crash like 2008.
- Practice risk-free$10,000 in virtual money to invest at real prices.
- Global screenerSearch US stocks and stocks from 47 countries with filters.
Plans from €3.99 a month.
ATLAS's model gives GRI Bio a 44% chance of finishing higher a month from now (21 trading sessions) than today: somewhat worse than a coin flip.
In half of the simulated outcomes the price ends between $1.22 and $1.72; in 9 out of 10, between $0.91 and $2.32. Estimated annual volatility is 96%.
Key numbers
- Market cap
- $4.3M
- Revenue (12 months)
- $0.0M
- Return on equity
- -142.0%
- Free cash flow (12 months)
- $-6.6M
- Beta
- -0.55
What this means
ATLAS does not publish a fair value for GRI right now, but it does show its odds of rising: somewhat worse than a coin flip.
Its beta is -0.55: it tends to move less than the market.
About the company
GRI Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases.
Want to see everything about GRI Bio?
Get started →Plans from €3.99 a month.
Comparable companies
Other companies in the same line of business:
Frequently asked questions
What does GRI Bio do?
GRI Bio Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory, fibrotic, and autoimmune diseases.
What is the chance GRI goes up next month?
44%: somewhat worse than a coin flip. In half of the simulated outcomes, GRI ends the month between $1.22 and $1.72.
How big is GRI Bio and what is its P/E ratio?
GRI Bio's market capitalization is $4.3M. We do not show a P/E because it has no positive earnings to base one on.
How volatile is GRI?
ATLAS estimates annual volatility at 96%. In a typical month, half of the outcomes end between $1.22 and $1.72.
Not investment advice. ATLAS estimates are produced by statistical models from public data; they can be wrong and past performance does not predict future results. Consider your own situation before investing. Disclaimer